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of PAX3-FOXO1. Combined treatment with an Aurora kinase A inhibitor and navitoclax in FP-RMS
cell lines and patient-derived xenografts synergistically induced cell death and significantly slowed tumor
growth. These studies identify a novel functional interaction of Aurora kinase A with both PAX3-FOXO1
and its effector MYCN, and reveal new opportunities for targeted combination treatment of FP-RMS.
DOI: https://doi.org/10.1158/0008-5472.CAN-19-1479





Ommer, Johannes; Selfe, Joanna L; Wachtel, Marco; O’Brien, Eleanor M; Laubscher, Dominik; Roem-
mele, Michaela; Kasper, Stephanie; Delattre, Olivier; Surdez, Didier; Petts, Gemma; Kelsey, Anna; Ship-
ley, Janet; Schäfer, Beat W (2020). Aurora A kinase inhibition destabilizes PAX3-FOXO1 and MYCN




Aurora A kinase inhibition destabilizes PAX3-FOXO1 and MYCN and synergizes 
with Navitoclax to induce Rhabdomyosarcoma cell death 
 
Johannes Ommer1, Joanna L. Selfe2, Marco Wachtel1, Eleanor M. O’Brien2, Dominik Laubscher1, 
Michaela Roemmele1, Stephanie Kasper1, Olivier Delattre4, Didier Surdez4, Gemma Petts3, Anna 
Kelsey3, Janet Shipley2, Beat W. Schäfer1 
 
 
1Department of Oncology and Children’s Research Center, University Children’s Hospital Zurich, Zurich, 
Switzerland  
2Sarcoma Molecular Pathology Laboratory, The Institute of Cancer Research, London, SM2 5NG, UK. 
3Department of Diagnostic Paediatric Histopathology, Royal Manchester Children's Hospital, 
Manchester, UK 
4 France INSERM U830, Équipe Labellisé LNCC, PSL Université, SIREDO Oncology Centre, Institut 
Curie, Paris, France 
 
Running title: AURKAi and BCL-XLi synergize to control FP-RMS tumor growth 
 
Conflict of interest: The authors declare no conflict of interest. 
 
Corresponding author:  
Beat W. Schäfer, PhD 
Department of Oncology, Children’s Hospital Zurich 
Steinwiesstrasse 75 
8032 Zurich, Switzerland 
Beat.schaefer@kispi.uzh.ch 
Phone: +41 (44) 266 7553 
Fax: +41 (44) 266 7171 
 
 





Statement of significance:  17  
Abstract: 248 
Main text: 4558 
Number of tables/figures: 6 Figures / 11 Supplemental Figures  





on January 23, 2020. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 




The clinically aggressive alveolar rhabdomyosarcoma subtype is characterized by expression 
of the oncogenic fusion protein PAX3-FOXO1, which is critical for tumorigenesis and cell survival.  
Here we studied the mechanism of cell death induced by loss of PAX3-FOXO1 expression and identified 
a novel pharmacological combination therapy that interferes with PAX3-FOXO1 biology at different 
levels. Depletion of PAX3-FOXO1 in fusion positive (FP)-RMS cells induced intrinsic apoptosis in a 
NOXA-dependent manner. This was pharmacologically mimicked by the BH3 mimetic navitoclax, 
identified as a top compound in a screen of 208 targeted compounds. In a parallel approach, and to 
identify drugs that alter the stability of PAX3-FOXO1 protein, the same drug library was screened and 
fusion protein levels were directly measured as a read-out. This revealed that inhibition of Aurora kinase 
A most efficiently negatively affected PAX3-FOXO1 protein levels. Interestingly, this occurred through a 
novel specific phosphorylation event in and binding to the fusion protein. Aurora kinase A inhibition also 
destabilized MYCN, which is both a functionally important oncogene and transcriptional target of PAX3-
FOXO1. Combined treatment with an Aurora kinase A inhibitor and navitoclax in FP-RMS cell lines and 
patient-derived xenografts synergistically induced cell death and significantly slowed tumor growth. 
These studies identify a novel functional interaction of Aurora kinase A with both PAX3-FOXO1 and its 
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Rhabdomyosarcomas (RMS) are the most common pediatric soft tissue sarcoma. The most aggressive 
subtype, alveolar Rhabdomyosarcoma, is characterized by the occurrence of balanced reciprocal 
translocations resulting in expression of oncogenic fusion proteins (1,2), whereby the most common 
fusion is PAX3-FOXO1. Fusion-positive RMS (FP-RMS) has a high propensity to metastasize and 
resistance to standard-of-care treatments are common, resulting in 5-year survival rates of only about 
30% (3-5). The search for novel targeting strategies is difficult as pediatric tumors generally harbor only 
few somatic mutations (6), which is especially true for the FP-RMS subtype (7). The lack of other somatic 
mutations underscores the important role of PAX3-FOXO1, which functions as transcriptional activator 
affecting multiple oncogenic pathways (8). We previously demonstrated that antisense-mediated loss of 
PAX3-FOXO1 results in cell death, underscoring the addiction of FP-RMS cells to the fusion protein. 
However, so far the exact mechanism by which the cells die has not been described (9). 
Due to its importance for tumor cell survival, therapeutic targeting of PAX3-FOXO1 has become a 
paramount goal of rhabdomyosarcoma research. One approach has been to identify key downstream 
effectors of the fusion protein as potential therapeutic targets, such as MYCN (10). However, since 
MYCN and PAX3-FOXO1 are transcription factors lacking enzymatic activity, targeting these proteins 
directly is challenging. Recently, new strategies have been developed targeting PAX3-FOXO1 indirectly 
by inhibiting its stabilizer Polo-like kinase 1 (PLK1) (11) or its co-factors, like bromodomain-containing 
protein 4 (BRD4) (12) or chromodomain-helicase DNA-binding protein 4 (CHD4) (13). Further strategies 
to target PAX3-FOXO1 and MYCN are reviewed in (14,15). While single-target therapies can be efficient 
in pre-clinical models and clinical treatment, they are prone to develop therapy resistance. One way to 
circumvent this problem is to use drug combinations that target different pathways preventing escape. 
Recently, we showed that PLK1 stabilizes PAX3-FOXO1 through phosphorylation of serines 
503 and 505, protecting the fusion protein from proteasomal degradation (11). While single-agent 
inhibition of PLK1 proved very effective in reducing tumor growth in vivo, resistance against this 
treatment was also observed. One of the regulators of PLK1 is Aurora A kinase (AURKA) which therefore 
might also functionally contribute to FP-RMS tumorigenesis.  Aurora kinases are a family of serine-
threonine kinases that are involved in cell cycle progression, most importantly during mitosis (16). 
AURKA is highest expressed at the G2/M transition (17) where it activates PLK1 by phosphorylation at 
threonine 210 as crucial step for checkpoint recovery (18,19). Furthermore, AURKA serves important 
roles in centrosome maturation and mitotic entry (20), as well as for spindle assembly (21). These 
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functions in cell cycle progression indicate an important role for Aurora kinases in cancer. Indeed, 
AURKA is upregulated in a variety of tumors and has thus become a focus of inhibitor development (22-
25). AURKA has also been shown to phosphorylate AKT and mTOR indicating a role in promoting 
chemotherapy resistance (26). 
Our goal was thus to find a novel synergistic combination therapy to treat FP-RMS. We 
demonstrate that FP-RMS cells undergo intrinsic apoptosis in a NOXA-dependent manner after loss of 
PAX3-FOXO1 which can be enhanced by the BH3-mimetic navitoclax (ABT-263). Moreover, we 
established a novel functional link between AURKA and stability of both PAX3-FOXO1 and MYCN. 
Combination of navitoclax and alisertib had synergistic anti-tumor effects in vitro and in vivo and thus 
provides the basis for a promising new rationale combination therapeutic approach for FP-RMS. 
 
Material and Methods 
 
Cell lines 
Rhabdomyosarcoma cell lines RD, Rh4 (Peter Houghton, St. Jude Children’s Hospital, Memphis, TN), 
RhJT (Scott Diede, Fred Hutchinson Cancer Research Center, Seattle, WA), RMS (Janet Shipley, 
Sarcoma Molecular Pathology, The Institute of Cancer Research, London, UK), KFR (Jindrich Cinatl, 
Frankfurter Stiftung für krebskranke Kinder, Frankfurt, Germany), Rh30 as well as HEK293T cells (both 
ATCC LGC Promochem) were cultured in high glucose DMEM (Sigma-Aldrich), supplemented with 100 
U/mL penicillin/streptomycin, 2 mmol/L L-glutamine, and 10% FBS (Life Technologies) at 37°C and 5% 
CO2. All RMS cell lines were authenticated upon receipt by short tandem repeat (STR) profiling, and 
used for experimentation from frozen stocks within 10-20 further passages. As the human myoblast cell 
line has not yet been characterized by STR profiling, negative matching with all available cell lines in 
the database was used for verification. All cells were regularly tested for mycoplasma contamination by 
a PCR based assay.  
 
Cells from patient-derived xenografts (PDX) 
PDX tumors were dissociated as described before (27). In brief, tumor tissue was minced with scalpels 
and suspended in Hanks’ Balanced Salt Solution (HBSS, Sigma-Aldrich) supplemented with 1 mmol/L 
MgCl2, 200 g/mL Liberase, and 200 U/mL DNase I (both Roche). Tissue was digested for 30 minutes 
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at 37°C and filtered twice through 70 m cell strainers (BD Biosciences). Dissociated cells were washed 
with phosphate-buffered saline (PBS, Sigma-Aldrich) before freezing or resuspending for further culture. 
Cells derived from PDX tumors were cultured in Neurobasal medium (Life Technologies) supplemented 
with 2x B-27™ Supplement (Life Technologies), 20 ng/mL EGF and 20 ng/mL basic FGF (Peprotech) 
on plates coated with Matrigel® (Corning Life Sciences). 
 
In vitro drugs screenings 
Cells were seeded in 384-well plates and shRNA was induced by 100 ng/ml doxycycline (Sigma-
Aldrich). Drugs (Supplemental Table 1) were purchased from Selleckchem and added to the cells using 
the HP D300 Digital Dispenser (Tecan). 24h after seeding cells, medium was changed to 19 l culture 
medium. Drugs were pre-diluted to 10 mol/l in culture medium and 1 l of each drug was added to the 
wells for a final concentration of 500 nmol/l. Viability was measured after 48h by WST-1 assay.  
Cells for immunoblot analysis were seeded in 24-well plates and drugs added at 100 nmol/l after 48h of 
incubation. 
 
Mouse xenograft experiments 
NOD/Scid il2rg-/- (NSG) mice were 8-12 weeks old for the experiments. 5x106 Rh4 or IC_PPDX35 cells 
were injected subcutaneously into the flanks. After engraftment mice were randomized into 4 groups (5-
6 mice per group) when tumors reached 100 mm3. Tumor growth was assessed by caliper 
measurements and the volumes were calculated using the formula V= (4/3) π r3; r=(d1+d2)/4). Mice 
were sacrificed when the tumor volume reached 1000 mm³. All animal experiments have been approved 
by the Swiss veterinary authorities (license ZH206/15). 
 
Statistics 
Data analysis was performed with GraphPad Prism 7. Significance was calculated using unpaired two-
tailed Student’s t-test or Welch’s two-tailed test. Two-way ANOVA was used for multiple comparisons. 
Differences were considered statistically significant with p<0.05. Drug synergy was calculated using the 
Bliss independence model in the free SynergyFinder WebApp (28).  
 
Additional methods see supplemental material and methods section.  
 
Research. 
on January 23, 2020. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 




Silencing of PAX3-FOXO1 expression induces intrinsic apoptosis in a NOXA-dependent manner 
Since it was previously shown that silencing of PAX3-FOXO1 expression results in FP-RMS cell death 
(9), we aimed first to further elucidate its precise mechanism.  
We generated FP-RMS cell lines expressing an inducible shRNA (shP3F) or control (shsc) to 
specifically silence PAX3-FOXO1 expression upon doxycycline treatment (Suppl.Fig.1A). After 
confirming that the system significantly downregulated the fusion protein both at the mRNA and protein 
level in four different cell lines (Suppl.Fig.1B-D), we assessed whether cells would undergo apoptosis. 
We observed a significant increase in caspase 3/7 activity in Rh4 and Rh30 cells after P3F depletion 
compared to control (Fig.1A, Suppl.Fig.1E). This increase was also reflected by the appearance of 
cleaved products of PARP, caspases 3, 7, and 9 (Fig.1B). To exclude off-target effects, we 
overexpressed a non-targetable PAX3-FOXO1 mutant which indeed could rescue cells from apoptosis 
despite silencing of the endogenous fusion protein as shown by reduced caspase 3/7 activity (Suppl. 
Fig1F) and decreased levels of cleaved PARP and caspase 3 protein products (Suppl. Fig.1G).  
To further confirm this notion, we also treated cells after fusion protein depletion with increasing 
concentrations of the pan-caspase inhibitor zvad-FMK which again could restore viability of shP3F-Rh4 
cells (Fig.1C) and reduced cleaved PARP and caspase 3 protein levels (Suppl.Fig.1H). To exclude other 
modes of cell death, we also treated cells with the different cell death inhibitors zvad-FMK (apoptosis) 
necrostatin-1 (necroptosis), ferrostatin (ferroptosis), as well as E64d (cathepsin inhibitor) and cathepsin 
GI. However, only zvad-FMK could rescue viability but none of the other inhibitors (Fig.1D). These data 
indicate that apoptosis is the major mode of cell death activated in FP-RMS cells upon depletion of 
PAX3-FOXO1. 
Next, we sought to identify the pro-apoptotic protein(s) responsible for initiating apoptotic cell 
death. We performed a small scale CRISPR/Cas9 screen in shP3F-Rh4 cells using the construct 
depicted in Suppl.Fig.2A to knock-out pro-apoptotic genes either individually or in combination, and 
measured cell viability upon P3F depletion. Knock-down efficiencies of Bax, Bak, Bad, Bim as examples 
are shown in Suppl.Fig.2B-C. In control cells (shsc-Rh4), only depletion of caspase 9, but not caspase 
8, and the combination of Bax/Bak were able to significantly reduce caspase 3/7 activity (Suppl.Fig.2D). 
This indicates that activation of the extrinsic pathway is less important in FP-RMS cells. Upon depletion 
of PAX3-FOXO1, NOXA was the only BH3-only protein capable to significantly reduce caspase 3/7 
activity (Fig.1E, Suppl.Fig.2E), similar to knock out of the pore forming proteins BAX and BAK. These 
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results were validated in three additional FP-RMS cell lines (Suppl.Fig.2F), albeit the extent of 
repression differed among cell lines. Nevertheless, NOXA seems to play an important role in initiating 
apoptosis after PAX3-FOXO1 depletion, although the contribution of other BH3-only proteins cannot be 
excluded. Furthermore, cell cycle analysis after PAX3-FOXO1 silencing (shP3FDox) indicated no 
significant change in cell cycle distribution but appearance of a sub-G1 peak in all cells except Rh30, 
indicative of induction of apoptosis (Suppl.Fig.2G). This is in line with the observation that both NOXA 
mRNA and protein expression are upregulated upon silencing of the fusion protein in all cell lines tested 
with the exception of Rh30 cells (Fig.1F-G, Suppl.Fig.2H). Taken together, our results demonstrate that 
intrinsic apoptosis initiated upon silencing of PAX3-FOXO1 depends on upregulation of the BH3-only 
protein NOXA.  
  
The BH3-mimetic navitoclax enhances cell death after PAX3-FOXO1 depletion 
Next, we aimed to find drugs that would enhance apoptosis induced by PAX3-FOXO1 depletion. For 
this, we set up a compound screen of 208 drugs at a final concentration of 500nM and treated shP3F-
Rh4 cells after doxycycline-mediated shRNA induction (Suppl.Fig.3A, Suppl. Table 1). Results are 
depicted as ratio of viability comparing shP3F versus shsc cells. The screen identified 13 candidate 
drugs that decreased viability by at least an additional 50% while remaining unchanged in control cells 
(Fig.2A, left panel; raw data Suppl. Table 2). Classification of the top hits according to their mechanism 
of action revealed that three of them are BH3-mimetics (Fig.2A, right panel) with navitoclax (ABT-263) 
being the most potent drug, also when validating each as single agent (Fig.2B, Suppl.Fig.3 B-M). To 
directly compared BCL-XL versus BCL-2 targeting, we generated dose-response curves for navitoclax 
and venetoclax (ABT-199) (Fig.2C-D). Interestingly, navitoclax reduced IC50 to at least a ten times lower 
concentration (reduction of 3.0M to 0.18M) than venetoclax (reduction of 9.6uM to 5.6uM). These 
findings suggest that inhibition of BCL-2 might be less important. To confirm this notion, we treated cells 
with increasing concentrations of an additional BCL-XL specific inhibitor, A1331852, and UMI-77 which 
is MCL-1 specific.  While A1331852 showed comparable effects to navitoclax (Fig.2E), treatment with 
UMI-77 did not further increase cell death (Suppl.Fig.3N). These results strengthen the observation that 
PAX3-FOXO1 silencing primes FP-RMS cells to apoptosis via balancing NOXA versus BCL-XL levels. 
To demonstrate this more directly, we treated shP3F-Rh4-NOXA-/- cells (Suppl.Fig.2E) with 
navitoclax and found indeed reduced sensitivity upon silencing of PAX3-FOXO1 (Fig.2F). Finally, 
expression analysis of different datasets in the r2 database (R2: Genomics Analysis and Visualization 
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Platform: http://r2.amc.nl) revealed that NOXA expression was elevated at base levels in all 
rhabdomyosarcoma datasets compared to healthy skeletal muscle tissue (Suppl.Fig.3O).  
These findings suggest that rhabdomyosarcoma cells might be already primed towards a pro-
apoptotic state through higher basal NOXA expression which can be further enhanced by reduction of 
fusion protein levels and renders them more sensitive towards navitoclax treatment.  
 
Aurora kinase A inhibition reduces PAX3-FOXO1 protein stability 
Next, we aimed to pharmacologically reduce PAX3-FOXO1 protein levels. To this end, we treated wild 
type Rh4 cells with the same drug library (Supplemental Table 1) and analyzed cell lysates by Western 
Blot (Suppl.Fig.4A). To exclude general toxic effects all signals were densitometrically digitalized and 
normalized to the house keeping protein GAPDH. Initial hits were called when fusion protein levels were 
lowered below 80%, a criterion fulfilled by 43 compounds (Fig.3A-B; raw data Suppl. Table 3). When 
classifying these hits according to their drug targets, we identified five epigenetic regulators, though 
HDAC inhibitors like entinostat, which was recently described to reduce fusion protein levels (29), 
showed only mild to no effects (Suppl. Fig 4B). Furthermore, we classified five proteasome, five AURKA, 
and three CDK9 inhibitors (Fig.3C). Strikingly, AURKA inhibitors were already identified in our apoptosis 
screen as hits (Fig. 2B), and previous work from our laboratory demonstrated a direct interaction 
between PAX3-FOXO1 and Polo-like kinase 1 (PLK1) which stabilizes the fusion protein (11) and is 
known to be activated by AURKA (19). Hence, we individually validated AURKA inhibitors at increasing 
doses and identified alisertib as being the compound active at the lowest doses tested (Fig.3D, 
Suppl.Fig.4C-D). Importantly, treatment of PDX-derived primary cells with alisertib also reduced fusion 
protein levels (Suppl.Fig.4D).  We were then interested to study the mechanism underlying the functional 
interaction of AURKA and PAX3-FOXO1. We treated Rh4 cells with alisertib which increased total 
protein levels of both PLK1 and AURKA, whereas we observed a reduction of PLK1 phosphorylation at 
threonine 210, as expected (Fig.3E). Since AURKA has been described to phosphorylate S256 in wild 
type FOXO1 (30), we then investigated phosphorylation of S437 in PAX3-FOXO1 (corresponding 
residue in wild-type FOXO1). Indeed, we also observed a clear reduction at this site upon alisertib 
treatment (Fig.3E). As this region of PAX3-FOXO1 has been described to be relevant for protein stability 
(reviewed in (15)), we next studied whether phosphorylation of S437 contributed to fusion protein 
stability by replacing serine with alanine. Interestingly, and actually even slightly more pronounced than 
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the previously described S503A mutant, the S437A mutant also significantly reduced fusion protein 
stability as revealed after 8hr treatment with cycloheximide (Fig.3F-G).  
Lastly, to investigate a potential direct interaction of AURKA and PAX3-FOXO1 we fused PAX3-
FOXO1 to the bacterial biotin-ligase BirA (31) and expressed it ectopically in HEK293T cells. After pull 
down of biotinylated proteins using streptavidin coated beads, PLK1 was identified on Western Blots in 
fusion protein samples but not in the BirA-only control, as shown before (32) (Fig.3H). Strikingly, also 
AURKA was identified in this assay as being selectively biotinylated, suggesting a novel direct 
interaction of this kinase and the fusion protein (Fig.3H).  
Taken together, our results indicate that AURKA inhibition can decrease fusion protein stability 
through reduced phosphorylation of serine 437 which might contribute to its ability to induce apoptosis 
in FP-RMS cells. 
 
Aurora kinase A inhibition also destabilizes MYCN in FP-RMS cell lines 
AURKA is reported to stabilize the MYCN protein that is highly expressed through transcriptional 
regulation by the fusion protein and genomic amplification (10,33-35). Previous studies showed that 
AURKA stabilizes MYCN by interfering with SCFFbxW7-mediated ubiquitination and that sequential 
phosphorylation of MYC proteins at S62 and T58 is required for binding of SCFFbxW7 (36,37). We 
therefore investigated whether AURKA inhibition affected MYCN protein levels in FP-RMS cells. We 
stably transduced three different FP-RMS cell lines with plasmids expressing shRNA against AURKA 
mRNA. In all cell lines depletion of AURKA resulted in reduced MYCN protein levels (Fig.4A). In 
accordance with published literature (38), MYCN double-mutants (T58A / S62A) had more stable MYCN 
and were rescued from degradation after depletion of AURKA in RMS cells (Fig.4B). This finding 
indicates that in FP-RMS cells MYCN stability is controlled by AURKA through the same mechanisms 
described for other cell types and cancers (39). Lastly, we wanted to confirm the influence of 
pharmacological AURKA inhibition on MYCN protein levels in FP-RMS cells. We treated different FP-
RMS cell lines with increasing concentrations of the AURKA inhibitors alisertib, as well as CCT137690 
(a kinase inhibitor), and CD532 (an amphosteric inhibitor with similarities to alisertib), respectively. In all 
cell lines, inhibition of AURKA resulted in loss of MYCN protein levels in a dose dependent manner at 
sub-micromolar doses (Fig.4C, Supp. Fig.5A-B).  
Taken together, our data shows that AURKA stabilizes MYCN in addition to its effects on PAX3-FOXO1 
and its inhibition destabilizes MYCN, a target gene of the fusion protein. 
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Alisertib and navitoclax act synergistically in vitro 
Since it is unlikely that single agents will be able to provide significant clinical benefit, we next wanted 
to identify a combination of synergistically acting drugs. To do this in an unbiased way, we screened our 
library for compounds that would synergistically reduce cell viability in conjunction with a non-effective 
concentration of navitoclax (IC20) (Suppl.Fig.6A-B; raw data Suppl. Table 4). We assessed cell viability 
after 48h and ranked the results according to synergism. Strikingly, out of the 28 hits identified, seven 
were AURKA inhibitors (Fig.5A). Six of these were also identified in a similar screen carried out in a 
second FP-RMS cell line (Suppl.Fig.6C-D). Hence, AURKA inhibitors might act in synergy with 
navitoclax. To test this, we treated FP-RMS cells with increasing concentrations of both alisertib and 
navitoclax to obtain a combination matrix. Indeed, the combination was able to induce cell death even 
at lower drug concentrations (Fig.5B) and was highly synergistic as assessed by SynergyFinder (28) 
(Fig.5C, Suppl.Fig7A). Importantly, we observed comparable synergistic effects not only in cell lines but 
also in six PDX-derived primary cells. This synergy was tumor specific as non-tumorigenic cells (human 
foreskin fibroblasts and myoblasts) were not sensitive towards the combination treatment despite 
expression of various levels of NOXA (Suppl.Fig.7B). NOXA-/- cells were also not sensitive to the 
combination treatment, demonstrating that NOXA expression was required (Suppl.Fig.8A-B). 
As AURKA plays an important role for cell cycle progression during G2/M phase, we assessed cell cycle 
distribution after alisertib or combination treatment. Treating cells with 50 or 100 nM alisertib, we 
observed an increasing proportion of cells arrested in G2/M phase (Fig.5D). Combination with 800nM 
navitoclax however strongly reduced the G2/M peak and increased the sub-G1 fraction (Fig.5D, 
Suppl.Fig.8C). This suggests that alisertib alone induces cell cycle arrest while in combination with 
navitoclax pushes cells into apoptosis. These findings are also supported by a synergistic increase in 
caspase 3/7 activity (Suppl.Fig.8D). Hence, alisertib acts synergistically with navitoclax in vitro to induce 
apoptosis in cell lines and primary PDX-derived RMS cells, while the drug combination had no major 
effects on non-tumorigenic cells.  
 
Combination of alisertib and navitoclax synergistically reduces tumor growth in vivo 
Having confirmed a synergistic action of alisertib and navitoclax in vitro, we next aimed to assess the 
anti-tumorigenic response of the combination in vivo. We injected NOD/Scid il2rg-/- (NSG) mice 
subcutaneously with either Rh4 or patient-derived IC_pPDX35 cells. After tumors were palpable, mice 
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were randomized into four groups and treated daily over three weeks with either vehicle, navitoclax 
alone (80 mg/kg), alisertib alone (30 mg/kg), or the combination of both drugs (Suppl.Fig.9A). While 
continuous tumor growth was observed in Rh4 cells in vehicle and navitoclax only treated mice, alisertib 
treatment slightly delayed tumor growth but failed to induce lasting effects (Fig.6A). In contrast, 
combination therapy resulted in modest tumor regression and lasting stable disease even after end of 
the treatment period (Fig.6A). This was also reflected in the survival of mice, since only animals in the 
combination group survived (Fig.6B). In the PDX model, alisertib treatment alone provoked a stronger 
delay in tumor growth albeit also in this setting, combination treatment showed the most stable growth 
control (Fig.6C) and survival was increased (Fig.6D). In neither experiment, we observed significant 
weight loss (Suppl.Fig.9B-C). To investigate whether alisertib treatment mimics PAX3-FOXO1 
depletion, we also performed an in vivo experiment with the doxycycline inducible shP3F line in 
combination with navitoclax. While silencing of the fusion protein alone already leads to significant 
growth inhibition, addition of navitoclax treatment has a further, albeit small, combinatorial effect (Suppl. 
Fig. 9D). We also isolated IC_pPDX35 tumors after one week of treatment, where histological analysis 
revealed a marked increase in the number of apoptotic cells in combination treated tumors (Fig.6E) and 
increased staining for cleaved caspase 3 (Fig.6E). Consequently, proliferation was reduced as 
monitored by Ki67 staining and increased expression of p21 (Suppl.Fig.9E,F).  
To underscore the clinical relevance of AURKA inhibition, we finally noticed that AURKA RNA 
expression is significantly higher in three independent rhabdomyosarcoma datasets compared to 
healthy skeletal muscle (Fig.6F) (data from R2 database: http://r2.amc.nl).  Further, we demonstrated 
AURKA protein expression in the majority of primary RMS. 26/37 (70%) of FP-RMS and 37/44 (84%) of 
FN-RMS stained positively for AURKA by IHC (Suppl.Fig.10A-B). In addition, AURKA and the 
proliferation marker Ki-67 showed a significant correlation in FN-RMS and a trend toward significance 
in FP-RMS (Suppl.Fig.10C-D).  This was consistent with significant correlations between AURKA and 
MKI67 at the mRNA level (Suppl.Fig.10E-F).  No significant correlations between AURKA 
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Our aim for this study was to identify a novel synergistic combination treatment strategy based on cell 
death mechanisms identified in FP-RMS following silencing of PAX3-FOXO1. We showed that cells 
undergo intrinsic apoptosis in a NOXA-dependent manner upon reduction of PAX3-FOXO1 protein 
levels. In accordance, we identified BH3-mimetics, specifically navitoclax, to efficiently enhance this 
mode of cell death. Furthermore, we demonstrated a novel functional interaction between AURKA and 
the fusion protein and observed strong synergy in vitro and in vivo with the AURKA inhibitor alisertib and 
navitoclax. 
We established a functional link between PAX3-FOXO1 and the BH3-only protein NOXA. 
However, we were unable to identify exactly how the fusion protein regulates NOXA expression. 
Previously, it was reported that PAX3-FOXO1 can upregulate basal Noxa levels in mouse myoblasts 
which could prime tumor cells to apoptosis (40). Indeed, we also found that NOXA levels in tumor cells 
are higher than in normal myoblasts. However, in ChIPseq data, we could not detect any binding of 
PAX3-FOXO1 to the genomic NOXA locus (41), excluding a direct role of the fusion protein in NOXA 
regulation. This is supported by the observation that NOXA levels even further increase when PAX3-
FOXO1 levels diminish. Since the cell lines used in our experiments are p53 deficient (42), this also 
excludes a role of p53 in NOXA regulation as previously described (43). However, it is well known that 
NOXA gene expression can be induced by a variety of cellular stresses such as hypoxia, DNA damage, 
genotoxic, ER or metabolic stress (44). If any of these and which one might be responsible for the 
observed phenotype remains to be investigated.  
Nevertheless, the observation that NOXA upregulation was required for apoptosis of FP-RMS 
cells led to the identification of navitoclax as sensitizer. This is in line with the previous identification of 
the BCL-XL inhibitor A-1331852 as sensitizer to chemotherapeutics (45). In addition, BCL-XL has been 
described as target gene of the fusion protein (46), which also explains the lower sensitivity of FP-RMS 
cells to venetoclax, targeting BCL-2. However, single agent activity is likely limited and therefore we 
searched for drugs capable to reduce fusion protein levels using conventional western blotting. This led 
to the identification of multiple AURKA inhibitors that also reduced MYCN protein levels, a functionally 
very important PAX3-FOXO1 target gene (35).  
Previously it was reported that fusion protein levels could be reduced by entinostat, an HDAC 
inhibitor (29). Conversely, in our screen for drugs affecting fusion protein levels, epigenetic regulators, 
like entinostat or SAHA do not show a striking effect. However, the drug concentrations used in our 
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screen, as well as incubation times (0.1 µM for 48h) are substantially lower than what was used by 
Abraham and colleagues (2 µM for 72h) (29). It is possible that these factors are the reasons for 
epigenetic regulators like entinostat not showing strong effects in our screen (Suppl. Fig. 3B). 
 Strikingly, we identified a new phosphorylation site in PAX3-FOXO1 (serine 437) that is 
important for fusion protein stability. This site corresponds to S256 in wild-type FOXO1, where it 
regulates nuclear exclusion and subsequent degradation (47) whereas phosphorylation of S437 in 
PAX3-FOXO1 stabilizes the fusion protein. These seemingly opposing effects on protein stability might 
suggest that protein turnover of wt versus the fusion protein are regulated by different mechanisms, as 
recently also suggested for the EWS-FLI1 fusion expressed in Ewing sarcoma (48). A similar 
observation has already been described for acetylation of K426 and K429 by the histone 
actyltransferase KAT2B that also stabilize PAX3-FOXO1 (49). Acetylation of the corresponding sites in 
wild-type FOXO1 results in phosphorylation at S256 and subsequent degradation (27). Hence, we might 
speculate that acetylated K426/K429 might contribute to stability through priming of the fusion protein 
for S437 phosphorylation. 
In the past, clinical trials involving navitoclax or alisertib have been challenging halting the 
process of clinical development. Navitoclax is known to increase the risk for thrombocytopenia due to 
its on-target effect (50). The advantage of our synergistic combination approach is that the individual 
drug doses can be lowered, thereby potentially reducing unwanted effects of each individual drug. 
Indeed, in our in vivo experiments we did not observe complications when using both drugs in 
combination. Furthermore, recent interest in these drugs increased and both companies are currently 
recruiting to new clinical trials (www.clinicaltrials.gov).  
Taken together, we identified a previously undescribed site in PAX3-FOXO1 that is important 
for fusion protein stability. With AURKA inhibition, we found a therapeutic option to target this site in the 
fusion protein while simultaneously also affecting MYCN levels (Suppl.Fig.11A-B). It is likely that both 
fusion protein and MYCN levels contribute to the inhibitory effects of alisertib since positive feedback 
mechanisms have been described regulating the expression of these two proteins [10, 12].  
Furthermore, by characterizing the exact mechanism of cell death associated with loss of fusion gene 
expression we were able to identify drugs that enhance this mode of cell death. When used in such a 
rationale combination, both drugs show a high degree of synergy both in vitro and in vivo, in cell lines 
and a RMS PDX model. These findings shed more light on a devastating disease and may offer novel 
therapeutic options for the treatment of patients with alveolar rhabdomyosarcoma.  
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Figure 1. Silencing of PAX3-FOXO1 induces apoptosis via NOXA 
A. Caspase activity after silencing of PAX3-FOXO1. Caspase 3/7 activity was assessed 24, 48 and 72 
hours after induction of shRNA expression in Rh4 cells. Mean of three independent experiments; bars, 
SD; 2-way ANOVA, ***, P ≤ 0.001. B. Western blot analysis of whole cell lysates from Rh4 shsc or 
shP3F 48h after shRNA induction with doxycycline (+) or no induction (-). C. Z-vad mediated rescue 
from cell death. WST-1 assay of Rh4 shsc or shP3F treated with doxycycline and increasing 
concentrations of z-vad FMK. Mean of two independent experiments; bars, SD; Student’s t test, *, P ≤ 
0.05, **, P ≤ 0.01. D. Rescue experiment after shRNA-mediated silencing of PAX3-FOXO1 mRNA. Rh4 
cells expressing either scrambled shRNA (shsc) or shRNA targeting PAX3-FOXO1 mRNA (shP3F) were 
treated for 48h with 0.1 µg/mL doxycycline to induce shRNA expression. Viability was assessed using 
WST-1 assay and shown relative to non-treated cells. Several cell death inhibitors were used at the 
concentration indicated. Mean of two independent experiments; bars, SD. E. BH-3 only protein screen. 
Caspase 3/7 activity of Rh4 shP3F cells harboring CRISPR/Cas9-induced knockouts of the indicated 
genes (sc = scrambled sgRNA). White bars, no shRNA induction; black bars, 48h after doxycycline-
induced shRNA expression. Mean of two independent experiments; bars, SD. F. NOXA expression after 
PAX3-FOXO1 silencing. Western blot analysis of whole cell lysates from Rh4 shsc or shP3F 48h after 
shRNA induction with doxycycline (+) or no induction (-). G. Relative mRNA expression of the PMAIP1 
gene in Rh4 shsc or shP3F 48h after induction of shRNA with doxycycline. Gene expression was 
normalized to GAPDH. Mean of two independent experiments. Each experiment was performed in 
triplicates. 
 
Figure 2. Navitoclax sensitizes cells to cell death after silencing of PAX3-FOXO1 
A. Drug screen to enhance cell death after silencing of PAX3-FOXO1. Rh4 shsc and Rh4 shP3F cells 
were treated with drugs (Supplemental Table 1) while simultaneously inducing shRNA expression with 
0.1 µg/mL doxycycline for 48h. Viability was measured by WST-1 assay and the relative viability effect 
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of each drug was calculated (see Method section). Left Panel: Plot shows the mean viability from 3 
independent experiments performed in duplicates. Right Panel: List of the top hits according to the ratio 
of relative viability of drugs on shP3F over shsc. Ranked according to their targeting class. SD = 
standard deviation; Welch’s two-tailed t-test, *, P ≤ 0.05, **, P ≤ 0.01, ***, P ≤ 0.001. B. Individual effect 
of Navitoclax on relative cell viability of Rh4 shsc or Rh4 shP3F compared to DMSO; SD; Welch’s two-
tailed t-test, **, P ≤ 0.01. C-E. Relative cell viability of Rh4 shsc or Rh4 shP3F cells after 48h with or 
without shRNA induction and simultaneous treatment with increasing concentrations of navitoclax, 
venetoclax or A-1331852, respectively. Mean +/- SD from three independent experiments performed in 
triplicates. IC50 values were calculated from non-linear regression analysis using GraphPad Prism® 7. 
F. Relative cell viability of Rh4 shsc PMAIP-/- or Rh4 shP3F PMAIP-/- cells treated with increasing 
concentrations of navitoclax for 48h. 
 
Figure 3. Inhibition of Aurora Kinase A leads to reduced PAX3-FOXO1 protein stability 
A. PAX3-FOXO1 protein levels were assessed by Western Blot 48h after treatment with 100 nmol/L of 
compounds (Supplemental table 1). Protein bands were analyzed by densitometry and normalized to 
GAPDH levels. Treatment was compared to DMSO. B. Exemplary blot of one set of drugs. Aurora 
Kinase A inhibitors are labelled in red. C: Chart showing the classes of inhibitors found among the top 
candidates. Red: Aurora Kinase A inhibitors, green: CDK9 inhibitors, grey: epigenetic modulators. D. 
Western Blot of lysates from Rh4 cells treated for 48h with increasing concentrations of the given drug. 
Left panel: Alisertib, right panel: AT9283. E. Immunoblot for phosphorylation at the indicated sites. Cells 
were incubated for 24h with alisertib and lysed with Co-IP buffer. F. Western Blot of RD cells transiently 
transfected with the respective overexpression plasmid for PAX3-FOXO1 mutants or wild-type (wt). 8h 
before lysis cells were treated with either 10 µg/mL cycloheximide (CHX) or DMSO to block protein 
synthesis. G. Densitometric quantification of the fusion protein levels, normalized to GAPDH. Mean of 
three independent experiments; bars, SD; two-way ANOVA, *, P < 0.05, **, P < 0.01. H. Western Blot 
analysis of streptavidin pull-down experiments. HEK293T cells were transduced with a PAX3-FOXO1 
expression plasmid fused to BirA biotin ligase (P3F-BirA) or with GFP or BirA alone. Cells were 
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Figure 4. Aurora kinase A regulates MYCN in rhabdomyosarcoma cells and affects MYCN protein 
stability.  
A. RMS cell lines were transduced with lentivirus containing control or Aurora kinase A (AURKA) shRNA 
(B and C) plasmids. Following selection, cells were lysed and immunoblotted for MYCN. MYCN was 
reduced in AURKA silenced cells in comparison to control shRNA treated cells. B. AURKA shRNA and 
control treated cells were transfected with V5-tagged MYCN (either wild-type (WT) or T58A/S62A mutant 
(MT) plasmid), lysed after 48 hours and immunoblotted with V5 antibody. V5-MYCN (wild type) was 
reduced in AURKA silenced cells compared to controls however V5-MYCN (mutant) was not, indicating 
that AURKA can regulate MYCN post-translationally in rhabdomyosarcoma cells by affecting protein 
stability. C. RMS-01 and RH4 were treated with increasing doses of alisertib and lysed after 48 hours to 
assess MYCN and PAX3-FOXO1 protein levels by immunoblot. 
 
Figure 5. Navitoclax and alisertib synergistically induce cell death in vitro 
A. Synergy screen. Rh4 cells were incubated with each drug (Supplemental Table 1) at a concentration 
of 500 nmol/L and additionally with either 800 nmol/L Navitoclax or DMSO. After 48h viability was 
assessed by WST-1 assay. Left y-axis: black bars, compound; grey bars, compound plus Navitoclax. 
Right y-axis, red bars: viability ratio (+Navitoclax/+DMSO). Top hits with a viability ratio < 0.7 are shown 
and ranked according to viability of each drug alone. Red stars: Aurora Kinase A inhibitors. Circle plot: 
28 top hits were classified according to their target spectrum: red, Aurora Kinase A inhibitors. B. Relative 
cell viability in percent after cross-titration of alisertib against Navitoclax in Rh4 cells. Cell viability relative 
to DMSO control was measured after 48h. Color scheme: high viability, blue; low viability: red. Mean 
values of three independent experiments performed in duplicates is depicted. C. BLISS synergy scores 
of Rh4 cells, indicated 6 PDX-derived primary cell cultures, human foreskin fibroblasts (HFF) and human 
myoblasts. Synergy was calculated according to the Bliss independence model using the SynergyFinder 
WebApp (28). Positive values (red) indicate synergy, negative values (green) indicate antagonism. E. 
Cell cycle analysis of Rh4 cells treated with given concentrations of Alisertib and additionally with either 
DMSO or 800 nmol/L Navitoclax. After 24h cells were stained with propidium iodide (PI) and cell cycle 
was analyzed by flow cytometry. Mean of two independent experiments.  
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Figure 6. Combination of Navitoclax and alisertib reduces tumor growth in vivo 
Rh4 or IC_pPDX35 cells were injected s.c. into the flanks of NSG mice. After engraftment, mice were 
randomized and assigned into one of four treatment groups: Vehicle (black), Navitoclax only (grey, 3d / 
week 80 mg/kg), Alisertib only (beige, 5d / week 30 mg/kg), Navitoclax + Alisertib combination (red). 
Mice were treated for 3 weeks with the respective regimen through administration p.o. (see also 
Suppl.Fig.7A) and sacrificed when tumors reached a size of 1000 mm3. 
A. Tumor growth of Rh4 cells in vivo. Black arrow: start of treatment. Red box indicates treatment period. 
Per group: n = 6; error bars, S.E.M. B. Kaplan-Meier graph showing percent survival of different 
treatment groups. Mantel-Cox test for comparison of survival curves, ***, p = 0.001 C. Tumor growth of 
IC_pPDX35 tumors. Black arrow: start of treatment. Red box indicates treatment period. Per group: n = 
5; error bars, S.E.M. D. Kaplan-Meier graph showing percent survival. E. Histology of engrafted 
IC_pPDX35 tumors after one week of treatment with either vehicle control (left panel) or combination of 
Navitoclax (80 mg/kg) and Alisertib (30 mg/kg) (right panel). N = 3. Upper panel: Hematoxylin & Eosin 
(HE) staining. Bars = 20 µm. Black arrows: apoptotic cells, red arrow: mitotic cell. Lower panel: 
Immunohistochemical staining against cleaved caspase 3. Bars = 50 µm. Representative images of 
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